In randomized studies (RCTs: MOBILITY, TARGET and MON-ARCH), and open-label [OLE] EXTEND, for those patients who experienced decreases in ANC this typically occurred early after initiating sarilumab. For sarilumab patients with decreased ANC in the RCTs and the OLE, we assessed the outcomes associated with either continuing treatment, decreasing the sarilumab dose or delaying the dose. Objectives: The effects of a dose decrease (200 to 150 mg), dose delay (>17 days), vs no change in treatment

more »

... re evaluated in RA patients who experienced decreased ANC while on sarilumab 150 or 200 mg q2w. Outcomes data from patients in MONARCH, MOBILITY and TARGET, and MOBILITY and TARGET patients entering EXTEND were analyzed to compare the three strategies. In MONARCH, patients received sarilumab 200 mg q2w. In MOBILITY and TAR-GET, patients received sarilumab 150 or 200 mg q2w. In EXTEND, patients were switched to, or initiated on, 200 mg q2w. Table 1 Outcomes following dose delay, dose decrease, or continued treatment with sarilumab among pts who experienced ANC <1000/mm 3 at any time